Cartesian Therapeutics, Inc.

company in Watertown, United States

RNAC Nasdaq SEC CIK 1453687
Follow Cartesian Therapeutics Weekly email: filings, results, news

Financials

Reported figures only · latest: Q2 2026 USD · US GAAP
Revenue, last quarter $0
Net income $15.8M −0.7% vs same quarter last year
EPS, diluted $0.46 −8% vs same quarter last year
Operating cash flow −$21.1M −20.3% vs same quarter last year
Revenue by quarter
$0
−$836K
$400K
$0
$0
$0
$0
$0
Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income13 fiscal years
  • Revenue
  • Net income
−$300M−$200M−$100M$0$100M$200MFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$400K−$130.3M
FY24$38.3M−$77.4M
FY23$26M−$219.7M
FY22$110.8M$35.4M
FY21$85.1M−$25.7M
FY20$16.6M−$68.9M
FY19$6.7M−$55.4M
FY18$903K−$65.3M
FY17$207K−$65.3M
FY16$8.1M−$36.2M
FY15$6M−$25.2M
FY14$3M−$12.9M
FY13--
MarginsShare of revenue
  • Operating margin
  • Net margin
−40000%−30000%−20000%−10000%0%10000%FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−35851.2%−32575.5%
FY24−114.7%−202.3%
FY23−332.3%−844.9%
FY2213.1%31.9%
FY21−5.4%−30.2%
FY20−342.4%−415%
FY19−785.6%−829%
FY18−7200.7%−7235.4%
FY17−30813.5%−31556%
FY16−428.9%−448%
FY15−421%−418.8%
FY14−506.5%−423.7%
FY13--
Free cash flowOperating cash flow minus capital expenditure
−$100M−$50M$0$50MFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$79.4M
FY24−$32.8M
FY23−$51.4M
FY22−$32.8M
FY21−$61.5M
FY20$34.1M
FY19−$51.5M
FY18−$60M
FY17−$52.8M
FY16−$20.3M
FY15−$23.6M
FY14−$12.9M
FY13-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Cartesian Therapeutics
  • Healthcare median
−40000%−30000%−20000%−10000%0%10000%FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearCartesian TherapeuticsHealthcare median
FY25−32575.5%−40.6%
FY24−202.3%−60.7%
FY23−844.9%−97.1%
FY2231.9%−128.5%
FY21−30.2%−129.2%
FY20−415%−136.5%
FY19−829%−133.7%
FY18−7235.4%−173.4%
FY17−31556%−176.7%
FY16−448%−164.8%
FY15−418.8%−183.4%
FY14−423.7%−133%
FY13-−88.5%

News

No stories filed under Cartesian Therapeutics yet - coverage appears here as the news feed clusters it.